AI Proteins, a biotech company pioneering a new class of de novo medicines built from the ground up using artificial intelligence, today announced the closing of a $41.5 million Series A financing. The round was led by Mission BioCapital and Sante Ventures, with participation from existing investors including Lightchain Capital, Cobro Ventures, and others.